Photo Gallery

Login

Search

News & Updation

  • WJPPS SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2018 Issue has been successfully launched on 1 September 2018

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  

Abstract

A STUDY ON ORAL OR INTRAVENOUS PROTON PUMP INHIBITOR IN PATIENTS WITH PEPTIC ULCER BLEEDING

Y. Srujana*, K. Anjali, K. Niharika, Sameena Begum, K. Kavitha and N. Prasanna Laxmi

ABSTRACT

Peptic ulcer disease (PUD) is a break in the lining of the stomach, first part of the small intestine or occasionally the lower esophagus.[1][7] An ulcer in the stomach is known as a gastric ulcer while that in the first part of the intestines is known as a duodenal ulcer.[1] We aimed to assess the clinical effectiveness of oral vs. intravenous (i.v.) regular-dose proton pump inhibitor (PPI) after endoscopic injection of epinephrine in patients with peptic ulcer bleeding. Patients were excluded from the study if they were pregnant, did not obtain initial haemostasis with endoscopic injection of epinephrine, did not give written informed consent, had bleeding tendency (platelet count <50 × 109 l−1, serum prothrombin<30% of normal, or were taking anticoagulants), had used PPI within 14 days of enrolment, had uraemia or bleeding gastric cancer. In summary, this single-centre, prospective, randomized, controlled trial of patients with high-risk bleeding ulcers has shown that oral and i.v. regular-dose PPI were equally effective as adjuvant pharmacotherapy to endoscopic haemostasis. Oral rabeprazole (20 mg twice daily) and i.v. infusion omeprazole (40 mg every 12 h) were not different in recurrent bleeding, surgery, blood transfusion or mortality. Our results suggest that oral PPI may be able to replace i.v. infusion PPI as the treatment of choice in peptic ulcer bleeding. However, more studies, particularly validating trials in Western countries, are necessary before oral PPI can be considered as the standard treatment.

Keywords: .


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More